Dr Khanani begins with the GALE study, which demonstrated that pegcetacoplan (PEG) provided benefit in visual function on a ...

Practice-changing studies in dry age-related macular degeneration (AMD) and promising new directions in wet AMD, presented at ...

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per ...

LumiThera's Valeda Light Delivery System generates light at different wavelengths to stimulate and improve the function of retinal mitochondria. The photobiomodulation (PBM) system is the first ...

Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...

Analyst Yigal Nochomovitz from Citi assigned a Buy rating on Apellis Pharmaceuticals (APLS – Research Report) and decreased the price ...

and separately in the PEGASUS phase III trial evaluating pegcetacoplan in patients with PNH previously treated with Soliris. Data will show that 5/84 patients (6.0%) in the ALPHA trial and 19/80 ...

and separately in the PEGASUS Phase III trial evaluating pegcetacoplan in patients with PNH previously treated with SOLIRIS. Data will show that 5/84 patients (6.0%) in the ALPHA trial and 19/80 ...

Apellis Pharma and partner Sobi have won EU approval for their paroxysmal nocturnal haemoglobinuria (PNH) drug pegcetacoplan in Europe, with a more restricted label than in the US. The European ...

A 36-week treatment regimen of pegcetacoplan reduces geographic atrophy growth rate while demonstrating a favorable safety profile.

Pegcetacoplan: Sold as Empaveli/Aspaveli by developer Apellis Pharma, pegcetacoplan has launched already in the US and Europe for rare blood disorder paroxysmal nocturnal hemoglobinuria (PNH ...